Singapore, 20 January 2025 – CDW Holding Limited, a SGX Mainboard-listed precision components and life sciences specialist, today announced that its subsidiary, A Biotech, has signed a joint research and development (R&D) agreement with South Korea’s Neoregen Biotech. The collaboration aims to drive innovation in next-generation Lipid Nanoparticle (LNP) technology, a key enabler for mRNA vaccines and advanced drug delivery systems.
Under the agreement, ABio and Neoregen will combine their proprietary know-how and technologies to deepen research into LNP technology and mRNA therapeutics. This partnership is expected to create significant synergies, leveraging Neoregen’s expertise in peptide-based drug delivery and ABio’s strengths in antibody development and recombinant antibody production.
LNP technology has emerged as one of the most successful nano-delivery vehicles for cytotoxic chemotherapy agents, antibody, and nucleic acid therapeutics, including mRNA vaccines. Its pivotal role was demonstrated during the COVID-19 pandemic, with LNP-based vaccines from Pfizer/BioNTech and Moderna. The global momentum for LNP-based mRNA therapeutics continues to accelerate, given their potential in vaccines and treatments for genetic diseases and cancers.
However, current LNP technologies face challenges, such as hypersensitivity reactions caused by polyethylene glycol (PEG) components and stability issues requiring strict temperature control. The joint R&D effort will explore whether CDW’s proprietary LANFA technology—a water-solubilised chemical compound that enhances hydrophilicity and solubility—can be applied to improve LNP safety and stability.
Mr. Kato Tomonori, Chairman and Chief Executive Officer of CDW Holding Limited, commented: “We are pleased to embark on this joint research and development venture with Neoregen Biotech. By combining Neoregen’s cutting-edge cell penetration LNP technology with CDW’s LANFA innovations, we aim to advance R&D in this field and potentially develop a breakthrough LNP product for the expanding market.”
The Group will provide further updates via SGXNet as material developments arise from this collaboration.
————
CDW Holding Limited (the “Company” and together with its subsidiaries, the “Group”) is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. The Company has been identifying new businesses to invest in with the potential for growth and entered as part of its diversification strategy and has made forays into the Life Sciences sector since 2016. The Company’s aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.
